SUPERNUS PHARMACEUTICALS, INC. (SUPN) Gross margin 2016–2025
SUPERNUS PHARMACEUTICALS, INC. (SUPN) gross margin by fiscal year — reported gross profit divided by reported revenue.
89.6%FY2025 · since FY2016: 94.4% → 89.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 89.6% | +1.4 pp |
| FY2024 | 88.2% | +2.0 pp |
| FY2023 | 86.2% | -0.7 pp |
| FY2022 | 86.9% | — |
| FY2020 | 89.9% | -5.8 pp |
| FY2019 | 95.8% | -0.5 pp |
| FY2018 | 96.2% | +1.3 pp |
| FY2017 | 95.0% | +0.5 pp |
| FY2016 | 94.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SUPN financial trends
SUPN RevenueSUPN Net incomeSUPN Net marginSUPN Gross profitSUPN Operating incomeSUPN Operating marginSUPN Operating cash flowSUPN Free cash flowSUPN Capital expendituresSUPN Return on equitySUPN Stock buybacksSUPN Dividends paidSUPN Total assetsSUPN Total liabilitiesSUPN Shareholders’ equitySUPN overview →